Antiviral Selection and Management of Potential Drug-Drug Interactions for COVID-19 in an Outpatient Setting

Enhance your knowledge of COVID-19 management for non-hospitalized patients with this comprehensive Q&A. Expert faculty have answered important questions on guideline recommendations for pharmacologic treatments and provided essential insights for navigating potential drug-drug interactions. Add this direct and practical resource to your clinical toolbox and feel equipped to treat COVID-19 in the outpatient setting. 

Learning Objectives

  • Describe guideline recommendations for the pharmacologic treatment of COVID-19 in non-hospitalized patients, including important considerations when selecting among antiviral therapies 
  • Discuss strategies to identify and manage potential drug-drug interactions (DDIs) in COVID-19 outpatient therapy 

Additional Information

Partner: 
Pri-Med Institute
Course summary
Available credit: 
  • 0.70 AANP Contact Hours
  • 0.70 AANP Pharmacology Contact Hours
  • 0.75 AMA PRA Category 1 Credit™
Course opens: 
11/15/2023
Course expires: 
11/15/2024
Rating: 
0

Available Credit

  • 0.70 AANP Contact Hours
  • 0.70 AANP Pharmacology Contact Hours
  • 0.75 AMA PRA Category 1 Credit™
Please login or register to take this course.

This course is offered through Pri-Med. 

 

To take this course you will be redirected to Pri-Med's website. You must login or create an account with Pri-Med in order to complete this activity. 

 

Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!